期刊
CANCER TREATMENT REVIEWS
卷 33, 期 3, 页码 299-313出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2006.12.005
关键词
bevacizumab; renal cell carcinoma; sorafenib; sunitinib; targeted therapy; temsirolimus
类别
资金
- NCI NIH HHS [N01 CM17101] Funding Source: Medline
Renal cell carcinoma (RCC) accounts for about 3% of all adult malignancies and its incidence is increasing. Smoking, obesity, and end-stage renal disease are important risk factors. Localized RCC may be cured with surgical excision. However, over one-third of patients eventually develop metastatic disease. White chemotherapy and radiation therapy are relatively ineffective for RCC, immunotherapy modestly extends survival and may lead to tumor regression and tong-term survival in a small minority of patients. Recently, research into the pathology of genetic syndromes associated with RCC has led to remarkable advances in our understanding of the pathogenesis of sporadic RCC. Rational therapeutic agents developed from this understanding have established new treatment paradigms for this disease. (C) 2007 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据